Raven Houston, PA-C

Raven Houston practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Raven Houston's NPI, 1235753351, was assigned on June 4, 2020. Raven Houston holds Texas license PA13849.

Raven Houston's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Raven Houston's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is UT Physicians. Dmand AI also links Raven Houston to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Raven Houston practices. Vendor and product names are available with a free account.

Physician assistant is Raven Houston's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Raven Houston is licensed in Texas.

CMS data shows 24 Medicare services from Raven Houston across 2 procedure codes in 2024, all of them office visits, for 28 Medicare patients. Medicare paid $827 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 28 Medicare patients who saw Raven Houston in 2024. The largest group is 75 to 84, with 16 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Raven Houston's median patient age at 70, with 51% women.

In 2024, Raven Houston wrote 58 Medicare Part D claims for 22 patients. 86% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Raven Houston for performance year 2024, reported as part of a group. Raven Houston accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 43 general payments to Raven Houston from 15 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 91% of the total. Sobi, Inc paid the most, $250.